Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516499 · ClinicalTrials.gov registry record
Neurofilament Surveillance Project (NSP)
A clinical trial of Frontotemporal Dementia and Frontotemporal Lobar Degeneration, sponsored by The Bluefield Project to Cure Frontotemporal Dementia.
- Active
- Registry status
- 342
- Enrollment target
- 8
- Study locations
NCT04516499: Active study of Frontotemporal Dementia and Frontotemporal Lobar Degeneration, sponsored by The Bluefield Project to Cure Frontotemporal Dementia.
NCT04516499 is a study of Frontotemporal Dementia and Frontotemporal Lobar Degeneration that is active but no longer recruiting, run by The Bluefield Project to Cure Frontotemporal Dementia. The registered enrollment target is 342 participants, below the 1,182-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (71% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04516499, a study of Frontotemporal Dementia and Frontotemporal Lobar Degeneration, is active but no longer recruiting, sponsored by The Bluefield Project to Cure Frontotemporal Dementia.
- ACTIVE NOT RECRUITING
- Registry status
- 342 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a biomarker study designed to collect and analyze blood specimens from individuals carrying known familial frontotemporal lobar degeneration (f-FTLD) mutations compared to a control group of individuals without known f-FTLD mutations. The NSP is an ancillary study to the ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration" (ALLFTD) study, NCT04363684. More information can be found at https://www.allftd.org/.
Primary Outcome
To determine the longitudinal stability of plasma neurofilament light chain (NfL) measured every 3 months for 36 months in individuals at-risk for symptomatic FTLD
Conditions Studied
Study Locations (8)
California
- University of California, San Francisco - San Francisco
Florida
- Mayo Clinic Florida - Jacksonville
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Massachusetts
- Massachusetts General Hospital - Charlestown
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University in St. Louis - St Louis
New York
- Columbia University - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2020-09-02 |
| Est. Completion | 2027-02 |
What the registry record for NCT04516499 still lists
NCT04516499 is an observational study that tracks outcomes without assigning an intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, below the 1,182-participant average among 22 other Frontotemporal Dementia trials with a reported enrollment target (71% lower).
The record links to 5 conditions, with Frontotemporal Dementia appearing as the primary indexed condition, and to 0 interventions.
NCT04516499 lists 8 locations in 8 states (California, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT04516499 about?
NCT04516499 is a clinical study titled "Neurofilament Surveillance Project (NSP)". This is a biomarker study designed to collect and analyze blood specimens from individuals carrying known familial frontotemporal lobar degeneration (f-FTLD) mutations compared to a control group of individuals without known f-FTLD mutations. The NSP is an ancillary study to the ARTFL LEFFTDS Longit...
What is the current status of trial NCT04516499?
This trial is currently active not recruiting. The enrollment target is 342 participants. The study started on 2020-09-02. Estimated completion is 2027-02.
What conditions does trial NCT04516499 study?
This clinical trial studies the following conditions: Frontotemporal Dementia, Frontotemporal Lobar Degeneration, FTD, FTD-GRN, FTLD.
Who is sponsoring clinical trial NCT04516499?
This trial is sponsored by The Bluefield Project to Cure Frontotemporal Dementia, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04516499 being conducted?
This trial has 8 study locations across California, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Frontotemporal Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04516499's enrollment target sits among peer trials
342 9th of 22 higher than 14 of 22 other Frontotemporal Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Frontotemporal Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
RECRUITING
-
Longitudinal Cognitive Assessment by BoCA
RECRUITING
-
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
RECRUITING · Phase 1
-
STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI